Pipeline

Focused on improving health outcomes for patients with multi-drug-resistant bacterial infections and hard-to-treat viral infections

Pipeline

Anti-infectives Portfolio

Venatorx Pharmaceuticals is pursuing novel chemical approaches to treat multi-drug resistant bacterial infections and hard-to-treat viral infections.

Venatorx has built a world-class in-house research and development organization that has filed over 120 patents. All investigational molecules were discovered internally.

Cefepime-Taniborbactam

Ceftibuten-Ledaborbactam Etzadroxil

PBP Inhibitors

Expanded Access

Venatorx Pharmaceuticals (the “Company”) is focused on conducting clinical studies and obtaining regulatory approval of investigational medicines in support of its mission to develop safe and effective treatments for infectious diseases. The best way for patients to get access to investigational medicines is by taking part in clinical trials. Please search ClinicalTrials.gov for publicly available information related to Venatorx’s ongoing clinical trials. READ MORE